| BACKGROUND
Research in the field of pig-to-primate xenotransplantation has made significant advances during the past 2 years, with life-supporting pig kidneys in non-human primates (NHPs) surviving for many months or even more than a year [1] [2] [3] and Tector AJ, personal communication). The results have been so encouraging that clinical trials are in the early stages of planning. 4, 5 There are some data that suggest that genetically engineered pig grafts transplanted into NHPs selected for no or low levels of anti-pig antibody, particularly IgG, survive longer than grafts transplanted into NHPs with higher levels of antibody.
In prospective clinical trials, if the initial patients are selected on the basis of no or low detectable levels of anti-pig antibody, will this be sufficient to ensure consistent prolonged graft survival or will additional genetic modifications, for example, expression of human complementor coagulation-regulatory proteins, be essential? Data from selected studies in which anti-pig antibody levels were known are here reviewed.
Evidence that selection of NHPs with no or low levels of anti-pig antibodies is associated with prolonged pig organ graft survival has slowly accumulated as the first studies of organ transplantation from pigs that did not express the important galactose-α1,3-galactose (Gal) antigens were reported in 2005. [6] [7] [8] The baboon recipients were selected for low anti-non-Gal antibody levels, that is, antibodies directed to the remaining pig antigens that were not Gal (non-Gal antigens) 9, 10 (Table 1) . Survival of heterotopic (non-life-supporting) heart grafts extended to 6 months 6,7 and of life-supporting kidney grafts to a little less than 3 months. 8 The discrepancy in graft survival between heart and kidney may not be simply related to whether or not the organ was life-supporting, as molecular differences may contribute to the poorer outcome of pig kidney grafts in NHPs. 11 However, whether orthotopic (life-supporting) heart xenograft survival will match heterotopic (non-life-supporting) heart xenograft survival has yet to be determined.
In baboons that did not develop complications associated with the immunosuppressive regimen, for example, infection, all heterotopic heart grafts developed thrombotic microangiopathy ( Figure 1 This was attributed to vascular endothelial activation by a low level of anti-pig antibody combined with incompatibility of coagulation factors between pig and baboon. As there was no evidence for an elicited (T-cell-mediated) antibody response, this activation was presumably associated with a continuing low level of production of natural (preformed) antibody, possibly in association with such factors as complement deposition and innate immune cell activity. These encouraging results could not be repeated when the selection of the recipient baboons was not based on low antibody levels (Table 1) .
14,15
The hypothesis that low antibody levels are important gained considerable support from studies in the GTKO/CD55 pigto-rhesus monkey kidney transplantation model. 1 Using an identical immunosuppressive regimen (based on costimulation blockade), a kidney transplanted into a monkey with a high level of antinon-Gal antibody functioned for only 6 days, whereas two with low antibody levels functioned for 6 and 10 months, respectively ( antibody levels, and all treated with an identical experimental protocol), in which the expression of different specific human complement-and coagulation-regulatory proteins on the pig kidney grafts resulted in a remarkable difference in graft survival from 12 days (n = 2) to >7 months (n = 2); (Table 1) . 3 (The poor results when kidneys from GTKO/CD46/hThrombomodulin pigs were transplanted, which were in contrast to excellent results when identical hearts were transplanted, 16 are likely related to the much greater expression of hThrombomodulin in the heart than in the kidneys in these Furthermore, the expression of human complement-± coagulationregulatory proteins can result in relatively prolonged graft survival even when the recipient NHPs have not been selected for low antibody levels (Table 1) , 2, 17, 18 with survival extending to >2 years. 16 These observations supported earlier studies in which the expression of a human complement-regulatory protein on GTKO pigs extended early graft survival in non-selected baboons. 19, 20 It should also be remembered that the original studies of pig organ transplantation in NHPs carried out by White, Cozzi, and their colleagues used pigs in which no pig antigens had been deleted (ie, wild-type pigs), but which expressed a human complement-regulatory protein,
CD55
. 21 When the pig was transgenic for a human complementregulatory protein, extensive studies in NHPs indicated that heart and kidney graft survival was significantly extended when compared with that of wild-type pig organs despite the fact that no attempt was made to reduce the levels of anti-pig antibody (reviewed in Ref 22 and Ref 23 ).
| RECENT PROGRESS
In the early pig-to-NHP organ transplantation studies, the only known pig antigen against which humans and NHPs had natural antibodies was Gal, 24 and so it was only possible to delete expression of this single antigen. It has long been known that pigs (but not humans) express N-glycolylneuraminic acid (Neu5Gc), 25 and there- "double-KO" pigs, that is, pigs that express neither Gal nor Neu5Gc
(GTKO/CMAHKO pigs), is significantly less than to cells from GTKO pigs (Figure 2 ).
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More recently, a third pig antigen target has been identi- In those humans in whom a low level of anti-TKO pig antibodies was identified, there was evidence that some of these antibodies may be directed to MHC swine leukocyte class I antigens (SLA-I). 32 The discrepancies in the results from different studies may be related to (i) the SLA phenotype of the specific pig from which the cells were derived, and/or (ii) the number of human sera tested, which was far greater in the studies by Martens and his colleagues. 32 Genetic engineering techniques will likely allow the specific SLA targets to be deleted in these pigs, allowing the patient to receive a pig graft against which he/ she has no antibodies. the upregulation of tissue factor expression on platelets was similar whether the platelets were exposed to wild-type, GTKO, or GTKO/ CD46 pig cells. 39 Unless the mechanism of the direct procoagulant effect of platelets and monocytes on vascular endothelial cells 38 can be elucidated and prevented, protection of an organ by expression of one or more coagulation-regulatory proteins may be very important.
In addition to antibody, complement, and platelets, cells of the innate immune system, for example, neutrophils, natural killer cells, and macrophages, may be playing a significant role. At present, their respective roles remain unclear, although natural killer cells may be adding to the inflammatory response to a pig xenograft. In addition, innate immune cells may be promoting/augmenting the adaptive immune response.
| CONCLUSIONS
What can be concluded from the data available to date? Current studies suggest that the major prerequisites for pig xenograft survival are (i) a low level of (or, preferably, no) preexisting natural anti-pig antibody, (ii) prevention of an elicited antibody response (secondary to efficient inhibition of a T-cell response), and possibly (iii) prevention of an inflammatory response. [40] [41] [42] To achieve these goals will require a combination of genetic engineering of the pig and effective immunosuppressive and anti-inflammatory regimens.
An important point that has to be addressed is whether the current It should also be noted that a further benefit of these genetic engineering approaches appears to be that deletion of an antigenic target, for example, Gal, or the expression of a human complement-regulatory protein, for example, CD46, both result in some reduction in the T-cell response to the graft, 43, 44 which in turn can mitigate T-cell-dependent B-cell activation and antibody production.
It could reasonably be argued that, if there is no evidence that expression of these human (transgenic) proteins is detrimental to the pig or to the recipient, for example, by acting as receptors for certain viruses and microorganisms, such as measles, 45 then their expression in all pig grafts will provide another level of protection that may prevent or at least delay the development of chronic rejection (eg, graft atherosclerosis), which remains a significant problem today in patients with long-term allografts. Expression of a human complement-regulatory protein in the pig organ may be particularly important in patients with high levels of natural anti-pig IgM (even if they have no anti-pig IgG).
Furthermore, not all complement activation is antibody-mediated, and so the expression of a human complement-regulatory protein might be protective against activation of the alternative complement pathway, for example, associated with ischemia-reperfusion, to which all xenografts will be exposed. Eventually, using genetic engineering techniques, it seems likely that it will be possible to provide a graft (that does not express any antigens against which the patient has preexisting antibodies) for any patient in need of an organ transplant (even patients who are highly sensitized to HLA). Long-term graft survival in successfully immunosuppressed patients would therefore be anticipated and perhaps further increased by the expression of selected human transgenes.
In turn, these genetic manipulations, particularly those that lead to "compatibility" of the pig and recipient MHC, will facilitate achieving the ultimate goal, namely the induction of tolerance to pig organs.
The recipient of the graft will need to receive an effective immunosuppressive regimen. It appears that, by increasing the genetic manipulation of the pig organ, conventional immunosuppressive therapy may be sufficient to prevent a T-cell response (and thus a T-cell-dependent 
